Tags

Type your tag names separated by a space and hit enter

Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ).
Pain Med. 2007 Apr; 8(3):281-8.PM

Abstract

OBJECTIVE

To characterize breakthrough pain (BTP), its qualitative impact on quality of life (QoL), and the effects of BTP treatment on QoL.

DESIGN

Multicenter patient-reported survey.

SETTING

Five pain treatment centers.

PATIENTS

Fifty-six adults with chronic noncancer pain using oral transmucosal fentanyl citrate (OTFC, ACTIQ).

RESULTS

Forty-three patients qualified for in-depth analysis. BTP had a mean intensity of 9.0 (range 5-10) on an 11-point numerical scale (0 = no pain to 10 = worst possible pain), had a mean duration of 83 minutes, and had an adverse effect on multiple QoL domains. The largest negative QoL impacts were on "general activity level" and "ability to work." OTFC had a positive impact on both controlling BTP and improving QoL.

CONCLUSIONS

BTP appears to be a clinically important condition in this population and is associated with an adverse impact on QoL. Understanding those QoL domains most affected by BTP and those potentially improved with treatment should help in developing quantitative QoL assessment tools and other outcome measures for BTP management studies.

Authors+Show Affiliations

Comprehensive Pain Care, Marietta, GA, Marietta, Georgia 30060, USA. dtaylor@cpcnopain.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17371416

Citation

Taylor, Donald R., et al. "Impact of Breakthrough Pain On Quality of Life in Patients With Chronic, Noncancer Pain: Patient Perceptions and Effect of Treatment With Oral Transmucosal Fentanyl Citrate (OTFC, ACTIQ)." Pain Medicine (Malden, Mass.), vol. 8, no. 3, 2007, pp. 281-8.
Taylor DR, Webster LR, Chun SY, et al. Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ). Pain Med. 2007;8(3):281-8.
Taylor, D. R., Webster, L. R., Chun, S. Y., Reinking, J., Stegman, M., Shoemaker, S., & Fortner, B. (2007). Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ). Pain Medicine (Malden, Mass.), 8(3), 281-8.
Taylor DR, et al. Impact of Breakthrough Pain On Quality of Life in Patients With Chronic, Noncancer Pain: Patient Perceptions and Effect of Treatment With Oral Transmucosal Fentanyl Citrate (OTFC, ACTIQ). Pain Med. 2007;8(3):281-8. PubMed PMID: 17371416.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ). AU - Taylor,Donald R, AU - Webster,Lynn R, AU - Chun,Steven Y, AU - Reinking,Jeffrey, AU - Stegman,Mary, AU - Shoemaker,Steven, AU - Fortner,Barry, PY - 2007/3/21/pubmed PY - 2007/5/23/medline PY - 2007/3/21/entrez SP - 281 EP - 8 JF - Pain medicine (Malden, Mass.) JO - Pain Med VL - 8 IS - 3 N2 - OBJECTIVE: To characterize breakthrough pain (BTP), its qualitative impact on quality of life (QoL), and the effects of BTP treatment on QoL. DESIGN: Multicenter patient-reported survey. SETTING: Five pain treatment centers. PATIENTS: Fifty-six adults with chronic noncancer pain using oral transmucosal fentanyl citrate (OTFC, ACTIQ). RESULTS: Forty-three patients qualified for in-depth analysis. BTP had a mean intensity of 9.0 (range 5-10) on an 11-point numerical scale (0 = no pain to 10 = worst possible pain), had a mean duration of 83 minutes, and had an adverse effect on multiple QoL domains. The largest negative QoL impacts were on "general activity level" and "ability to work." OTFC had a positive impact on both controlling BTP and improving QoL. CONCLUSIONS: BTP appears to be a clinically important condition in this population and is associated with an adverse impact on QoL. Understanding those QoL domains most affected by BTP and those potentially improved with treatment should help in developing quantitative QoL assessment tools and other outcome measures for BTP management studies. SN - 1526-2375 UR - https://www.unboundmedicine.com/medline/citation/17371416/Impact_of_breakthrough_pain_on_quality_of_life_in_patients_with_chronic_noncancer_pain:_patient_perceptions_and_effect_of_treatment_with_oral_transmucosal_fentanyl_citrate__OTFC_ACTIQ__ L2 - https://academic.oup.com/painmedicine/article-lookup/doi/10.1111/j.1526-4637.2007.00298.x DB - PRIME DP - Unbound Medicine ER -